REFERENCES
- Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Enql J Med. 1998;338:853–860.
- Saves M, Vandentorren S, Daucourt V, et al. Severe he-patic cytolisis incidence and risk factors in patients treated by antiretroviral combination. Aquitaine Cohort, France, 1996–98. AIDS. 1999;13:F115–121.
- Vento S, Garofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combi-nation therapy. AIDS. 1998;12:116–117.
- den Brinker M, Wit RN, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepato-toxicity of highly active antiretroviral therapy in HIV-1 infec-tion. AIDS. 2000;14: 2895–2902.
- Martinez E, Blanco JL, Arnaiz J, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 200115: 1261–1268.
- Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz containing antiretroviral therapy. Role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
- Rancinan C, Neau D, Saves M, et al. Is hepatitis C co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS. 2002;16:1357–1362.
- Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 200127: 316–318.
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
- NOriez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after intro-duction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:426–431.
- Orenstein R, Tsogas N. Looking beyond highly active antiretroviral therapy: drug-related hepatoxicity in patients with human immunodeficiency virus infection. Pharmaco-therapy. 2002;22:1468–1478.
- Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity asso-ciated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2002;34:1259–1263.
- John M, Flexman J, French MAH. Hepatitis C virus-associ-ated hepatitis following treatment of HIV-infected patients with protease inhibitors: an immune restoration disease? AIDS. 1998;12: 2289–2293.
- Martin-Carbonero L, NOriez N, Rios P, Pérez-Olmeda M, Gonzelez-Lahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS. 2002;16:1423–1425.
- Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Enql J Med. 2002;346:2039–2046.
- Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibi-tor-based antiretroviral regimens with or without concur-rent ritonavir. AIDS. 2004;18:2277–2284.
- Gonzalez-Requena D, NOriez M, Jiménez-Nacher I, Gonzelez-Lahoz J, Soriano V. Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or with-out hepatitis C coinfection. AIDS Res Hum Retroviruses. 2004;20:698–700.
- Meraviglia P, Schiavini M, Castagna A, et al. Lopinavir/ ritonavir treatment in HIV antiretroviral-experienced pa-tients: evaluation of risk factors for liver enzyme elevation. HIV Med. 2004;5:334–343.
- Bonfanti P, Ricci E, Penco G, et al. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS 2005;19:1433–1434.